Salute e Benessere
Drug-Eluting Stent Market to Hit USD 9.47 Billion by 2030, Says Mordor Intelligence
The global drug-eluting stent (DES) market is undergoing a period of transformation, with several emerging trends influencing growth, competition, and adoption across healthcare systems. From procedure backlogs and technology upgrades to evolving reimbursement policies and demographic shifts, these factors are redefining how hospitals, physicians, and manufacturers engage with this critical segment of cardiac care.
Elective procedure backlogs have driven PCI volumes beyond pre-pandemic levels, prompting hospitals and distributors to adopt more flexible, demand-driven stent planning. Early adopters of radial-access techniques are seeing faster growth in utilization.
Stronger safety data and reduced therapy needs are accelerating the shift to second- and third-generation drug-eluting stents. Hospitals are phasing out older models and using tiered inventories to balance cost with complexity.
Broader reimbursement policies, especially in emerging markets, are enabling wider adoption of advanced stents. Manufacturers are supporting this by pairing regulatory filings with health-economic data to secure faster inclusion in national formularies.
Rising elderly populations are driving demand for ultrathin-strut stents and advanced imaging. Hospitals are upgrading technology to manage complex cases, while payers adjust reimbursement to reflect higher-acuity care.
Despite advancements, safety concerns like late-stent thrombosis still challenge the drug-eluting stent market, pushing regulators to demand longer trials and raising costs for smaller firms. Growing adoption of OCT is also shifting preferences toward stents with better visibility.
Meanwhile, pricing pressure from group purchasing organizations in mature markets continues to squeeze margins. To counter this, major players are adding value-driven services, while regional manufacturers focus on smaller hospitals and niche markets less affected by price consolidation.
Strong reimbursement and early tech adoption keep North America in the lead, with outpatient shifts reshaping buying cycles and new approvals boosting demand.
The fastest-growing region, where cost-driven local players and global innovators coexist. Mature markets like
Japan focus on refinements, while
India and Indonesia drive growth through DES adoption.
A crowded market shaped by tenders and evidence-led practice. With outcomes showing little variation across coatings, cost and deliverability drive purchasing, pushing makers to innovate in complex cases.
https://www.mordorintelligence.com/industry-reports/drug-eluting-stent-market?utm_source=prnewswire
https://www.mordorintelligence.com/industry-reports/drug-eluting-stent-market/companies?utm_source=prnewswire
Drug-Eluting Balloons (DEB) market is projected to grow from USD 0.79 billion in 2025 to USD 1.19 billion by 2030, reflecting a healthy CAGR of 8.5%. Growth is being fueled by quicker regulatory approvals, clearer reimbursement pathways, and a steady rise in cardiovascular procedures. What was once seen as a niche solution for in-stent restenosis is increasingly becoming a mainstream tool for revascularization.
Coronary Stents Market is expected to grow from USD 8.29 billion in 2025 to around USD 10.43 billion by 2030, reflecting a CAGR of 4.7%. Market expansion is being driven by stable procedure volumes, the transition toward value-based care, and wider use of AI-powered imaging that enhances accuracy while minimizing complications. Hospitals increasingly prefer drug-eluting stents with ultrathin struts that support shorter dual antiplatelet therapy, while procurement reforms in Asia continue to influence global pricing strategies.
Peripheral Stents Market is projected to rise from USD 5.75 billion in 2025 to USD 8.19 billion by 2030, growing at a CAGR of 7.3%. This momentum is fueled by the increasing prevalence of peripheral artery disease (PAD), steady advances in stent technology, and the wider adoption of minimally invasive procedures that help shorten recovery times. Longer life expectancy, expanding procedure volumes, and the rise of ambulatory surgical centers (ASCs) further support demand
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
media@mordorintelligence.com
Mordor Intelligence Private Limited
https://www.mordorintelligence.com/
Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/drug-eluting-stent-market-to-hit-usd-9-47-billion-by-2030--says-mordor-intelligence-302538821.html